Definium Therapeutics (DFTX) Stock Price, News & Analysis

Company Overview

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Key Stats

• Today's Range: $41.25 to $44.46
• 50-Day Range: $24.16 to $48.45
• 52-Week Range: $8.70 to $49.70
• Volume: 1.73 million shs
• Average Volume: 2.27 million shs
• Market Capitalization: $5.81 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $63.00
• Consensus Rating: Buy

Definium Therapeutics Stock Analysis - MarketRank™

Definium Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 320th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Definium Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 17 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Definium Therapeutics has a consensus price target of $63.00, representing about 45.6% upside from its current price of $43.27.

Amount of Analyst Coverage

Definium Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Definium Therapeutics are expected to grow in the coming year, from ($3.02) to ($1.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Definium Therapeutics is -12.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Definium Therapeutics is -12.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Definium Therapeutics has a P/B Ratio of 12.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.04% of the float of Definium Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Definium Therapeutics has a short interest ratio ("days to cover") of 6.59.

Change versus previous month

Short interest in Definium Therapeutics has recently increased by 0.92%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Definium Therapeutics does not currently pay a dividend.

Dividend Growth

Definium Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.62

News Sentiment

Definium Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Definium Therapeutics this week, compared to 7 articles on an average week.

Search Interest

Only 18 people have searched for DFTX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

16 people have added Definium Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 78% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Definium Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,165,763.00 in company stock.

Percentage Held by Insiders

2.40% of the stock of Definium Therapeutics is held by insiders.

Percentage Held by Institutions

27.91% of the stock of Definium Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:DFTX
• CIK: 1813814
• Web: definiumtx.com
• Phone: 212 220 6633
• Fax: N/A
• Employees: 40
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Definium Therapeutics: $63.00
• High Price Target: $90.00
• Low Price Target: $25.00
• Potential Upside/Downside: +45.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$183.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.01%
• Return on Assets: -63.66%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 6.95
• Quick Ratio: 6.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.36 per share
• Price / Book: 12.88

Miscellaneous

• Outstanding Shares: 134,370,000
• Free Float: 131,142,000
• Market Cap: $5.81 billion
• Optionable: Optionable
• Beta: 2.23